Iron- and erythropoietin-resistant anemia in a spontaneous breast cancer mouse model

• Published in: Haematologica (Roma) Vol. 107; no. 10; pp. 2454 - 2465
• Main Authors: Bregolat, Nuria Fabregas, Ruetten, Maja, Da Silva, Milene Costa, Aboouf, Mostafa A., Ademi, Hyrije, Büren, Nadine von, Armbruster, Julia, Stirn, Martina, Altamura, Sandro, Marques, Oriana, Rodriguez, Josep M. Monné, Samillan, Victor J., Singh, Rashim Pal, Wielockx, Ben, Muckenthaler, Martina U., Gassmann, Max, Thiersch, Markus
• Format: Journal Article
• Language: English
• Published: Fondazione Ferrata Storti 01.10.2022; Ferrata Storti Foundation
• Subjects: Platelet Biology & its Disorders
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.2022.280732

Anemia of cancer (AoC) with its multifactorial etiology and complex pathology is a poor prognostic indicator for cancer patients. One of the main causes of AoC is cancer-associated inflammation that activates mechanisms, commonly observed in anemia of inflammation, whereby functional iron deficiency and iron-restricted erythropoiesis are induced by increased hepcidin levels in response to raised levels of interleukin-6. So far only a few AoC mouse models have been described, and most of them did not fully recapitulate the interplay of anemia, increased hepcidin levels and functional iron deficiency in human patients. To test if the selection and the complexity of AoC mouse models dictates the pathology or if AoC in mice per se develops independently of iron deficiency, we characterized AoC in Trp53floxWapCre mice that spontaneously develop breast cancer. These mice developed AoC associated with high levels of interleukin-6 and iron deficiency. However, hepcidin levels were not increased and hypoferremia coincided with anemia rather than causing it. Instead, an early shift in the commitment of common myeloid progenitors from the erythroid to the myeloid lineage resulted in increased myelopoiesis and in the excessive production of neutrophils that accumulate in necrotic tumor regions. This process could not be prevented by either iron or erythropoietin treatment. Trp53floxWapCre mice are the first mouse model in which erythropoietin-resistant anemia is described and may serve as a disease model to test therapeutic approaches for a subpopulation of human cancer patients with normal or corrected iron levels who do not respond to erythropoietin.